

## ExpreS<sup>2</sup>ion and GenIbet sign collaboration agreement for vaccine development and GMP production

ExpreS<sup>2</sup>ion Biotech Holding AB's fully owned subsidiary ExpreS<sup>2</sup>ion Biotechnologies ApS ("ExpreS<sup>2</sup>ion") has signed a collaboration agreement regarding vaccine development and GMP (Good Manufacturing Practice) manufacturing with its Portuguese partner GenIbet Biopharmaceuticals, S.A. ("GenIbet"). The agreement strengthens ExpreS<sup>2</sup>ion's position as a full-service provider from discovery up to early clinical development.

The parties have signed a Memorandum of Understanding (MoU) that enables ExpreS<sup>2</sup>ion to service customers and collaboration partners across the full value chain of development of vaccines, from discovery up till GMP production and clinical trials. GenIbet, an experienced vaccine contract development manufacturing organisation (CDMO), will serve as a preferred GMP partner of ExpreS<sup>2</sup>ion. The agreement is ongoing until further notice and contains no financial exchange between the parties.

*"We are pleased to add the capabilities of GenIbet, a recognised partner in vaccine production, into the service packages we offer to our clients and partners. This strategic alliance strengthens our position as a one-stop solution provider of external preclinical as well as and early clinical vaccine development," says ExpreS<sup>2</sup>ion CEO Dr. Steen Klysner.*

*"GenIbet's experience in GMP production and technology transfer of human and animal recombinant proteins is a great match for ExpreS<sup>2</sup>ion's platform technology. This collaboration agreement will expand the commercial opportunities in the vaccine field for both organisations," says GenIbet CEO Dr. Raquel Fortunato.*

In December 2017, ExpreS<sup>2</sup>ion signed a similar collaboration agreement with its partner Intravacc, which is based in the Netherlands. By having two strong preferred GMP partners with complementary skill sets and regional outreach, ExpreS<sup>2</sup>ion now has a broad and global offering with substantial GMP production capacity.

### About GenIbet

GenIbet, based in Oeiras, Portugal, is an established CDMO from 2006. GenIbet offers cGMP manufacturing excellence and a comprehensive service that encompasses cell line development, process and analytical development and cGMP production of recombinant proteins, DNA, Viral and Cell products. GenIbet leverages its activities on the extensive expertise in molecular biology, virology, microbial and cell culture of our partner and main shareholder, iBET (Instituto de Biologia Experimental e Tecnológica). More information can be found at [www.genibet.eu](http://www.genibet.eu).

### For further information about GenIbet, please contact:

Dr. Raquel Fortunato, CEO  
Telephone: + 351 21 137 21 74  
E-mail: [raquel.fortunato@genibet.com](mailto:raquel.fortunato@genibet.com)

### Certified Adviser

Sedermera Fondkommission is appointed as Certified Adviser for ExpreS<sup>2</sup>ion.

### For further information about ExpreS<sup>2</sup>ion Biotech Holding AB, please contact:

Dr. Steen Klysner, CEO  
Telephone: +45 2062 9908  
E-mail: [sk@expres2ionbio.com](mailto:sk@expres2ionbio.com)

*This press release contains information that ExpreS<sup>2</sup>ion is obligated to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above on May 29, 2018.*

ExpreS<sup>2</sup>ion Biotech Holding AB  
Press Release, 2018-05-29



---

**About ExpreS<sup>2</sup>ion**

ExpreS<sup>2</sup>ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS<sup>2</sup>ion Biotech Holding AB with company register number 559033-3729. The subsidiary has developed a unique proprietary platform technology, ExpreS<sup>2</sup>, that can be used for fast and efficient preclinical and clinical development as well as robust production of complex proteins for new vaccines and diagnostics. Since the Company was founded in 2010, it has produced more than 250 proteins and 35 virus-like particles (VLPs) in collaboration with leading research institutions and companies, demonstrating superior efficiency and success rates. In addition, ExpreS<sup>2</sup>ion develops novel VLP based vaccines through the joint venture AdaptVac ApS that was founded in 2017.